Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons And Share Price Target

Thu Apr 09 2026

Sun Pharmaceutical Industries is trading at Rs 1,580, down -20% from its 52-week high of Rs 2,000. The sustained decline in the Sun Pharmaceutical Industries share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff. This article explains every key reason behind the Sun Pharmaceutical Industries share price falling and provides a structured share price target for 2026.

Table of Contents

About Sun Pharmaceutical Industries

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries (NSE: SUNPHARMA) is a leading listed company in the Pharma sector with a market capitalisation of Rs 3,79,000 Cr. At approximately 38x P/E and 6.8x price-to-book, the stock’s 52-week range spans from Rs 1,480 to Rs 2,000. The current CMP of Rs 1,580 sits in the lower quarter of that range.

Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons

Tap to Access Best Research Pieces on Univest

1. US Specialty Business Growth Decelerating

Sun Pharma’s branded US specialty business — anchored by Ilumya (psoriasis), Cequa (dry eye), and Odomzo (basal cell carcinoma) — has been the primary driver of valuation premium over Indian pharma peers. Revenue from this specialty business grew at 25-30% CAGR through FY22-FY25. In Q3 FY26, growth decelerated to approximately 15% CC — still strong, but below the 20-25% the market had embedded in its target price assumptions.

2. Ilumya and Cequa Revenue Plateau

Ilumya, Sun Pharma’s IL-23 inhibitor for psoriasis, faces biosimilar competition beginning in 2026-27 as the compound patent protection window shortens. Cequa, for dry eye, faces intensifying competition from Xiidra (Novartis) and emerging therapies. Revenue plateauing in these two flagship products — which together contribute approximately 40% of Sun Pharma’s US specialty revenue — is the key concern for specialty trajectory.

3. India Field Force Restructuring Cost Inflation

Sun Pharma is restructuring its India pharma field force to improve productivity and reduce overlap between the branded generic and OTC businesses. This restructuring involves voluntary retirement schemes, territorial realignment, and product portfolio rationalisation — all of which carry one-time costs that compress Q4 FY26 and Q1 FY27 PAT margins.

4. Forex Headwinds on International Markets

Sun Pharma’s international business (excluding the US) includes meaningful revenue from emerging markets — Russia, South Africa, Brazil, and the Middle East. Currency weakness in several of these markets reduces reported revenue and PAT in rupee terms even when underlying volumes are healthy.

5. Premium Valuation Relative to Indian Pharma Peers

At 38x P/E, Sun Pharma commands the highest valuation multiple among large-cap Indian pharma companies. This premium reflects the specialty US business quality, but at 38x with a decelerating specialty growth rate, any further slowdown triggers disproportionate de-rating.

Sun Pharmaceutical Industries Latest News That Impacted the Stock

Q3 FY26 results (February 2026): Revenue Rs 13,268 crore (+10% YoY), PAT Rs 2,839 crore (+8% YoY). US specialty revenue growth 15% CC — below 20% estimate.

February 2026: Ilumya biosimilar approved by FDA for review — biosimilar entry possible by FY28.

March 2026: India field force restructuring costs — Rs 200-250 crore one-time charge in Q4 FY26 expected.

April 2026: Large-cap pharma FII selling. Sun Pharma tests 52-week low zone.

Financial Performance Analysis

The quarterly numbers below highlight the key metrics versus the year-ago quarter for Sun Pharmaceutical Industries.

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 13,268 Cr	Rs 12,061 Cr	+10.0%
Net Profit	Rs 2,839 Cr	Rs 2,628 Cr	+8.0%
EBITDA Margin	27.8%	28.2%	-40 bps
US Specialty Rev	Rs 3,200 Cr	Rs 2,783 Cr	+15% CC

Track Sun Pharmaceutical Industries live financials on Univest Screener

Technical Signals: What the Charts Are Saying

Sun Pharma is at Rs 1,580, approaching its 52-week low of Rs 1,480. Below the 50 and 100-day moving averages. Support at Rs 1,480-1,520. Resistance at Rs 1,750-1,800.

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries live.

Market Sentiment & Institutional Positioning

Promoter (Shanghvi family) holds 54.5%. FII at 21.8% — high by pharma sector standards. DII at 16.4%.

Future Outlook: Can Sun Pharmaceutical Industries Recover?

Sun Pharma’s long-term story — building India’s first global specialty pharma company — remains compelling. The specialty pipeline (TildrakizumAb, GL0034 GLP-1, and SCD-044 atopic dermatitis) offers genuine upside over 3-5 years. Recovery catalysts: Ilumya not losing significant market share to biosimilars in FY27, new specialty launches contributing meaningfully, and India business returning to 12-14% growth. The contrarian view: specialty drug investing is high-risk and 38x P/E provides limited cushion for any pipeline setback.

Sun Pharmaceutical Industries Share Price Target

Subscribe to Univest Pro for Premium Stock Research and F&O Setups

Short-Term Target (3–6 Months)

Short-term support and range: Rs 1,480-1,650. The stock may stay in this band while headwinds persist.

12-Month Analyst Target

The 12-month analyst consensus for Sun Pharmaceutical Industries is Rs 1,900-2,100, implying meaningful recovery potential from Rs 1,580.

Long-Term Target (2027–2028)

In a recovery scenario, the FY28 long-term target is Rs 2,500-2,800. Track live on Univest Screener.

Conclusion

Sun Pharmaceutical Industries share price falling -20% from Rs 2,000 reflects sector headwinds and company-specific pressures. The 12-month analyst consensus of Rs 1,900-2,100 implies recovery potential. Short-term support is Rs 1,480-1,650. For more analysis, visit

Univest Blogs

Disclaimer: This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

FAQs

Q1. Why is Sun Pharma share price falling?

Sun Pharma’s share price is falling due to US specialty revenue growth decelerating from 25-30% to 15% CC in Q3 FY26, Ilumya facing biosimilar approval review, Cequa facing intensifying competition, India field force restructuring one-time costs, forex headwinds on emerging market revenues, and premium 38x P/E vulnerable to any growth slowdown.

Q2. What is Sun Pharma share price target for 2026?

The 12-month analyst consensus is Rs 1,900-2,100. MOFSL targets Rs 2,000, YES Securities targets Rs 2,100. Short-term support is Rs 1,480-1,520.

Q3. What is Sun Pharma’s US specialty business?

Sun Pharma’s US specialty business includes Ilumya (IL-23 inhibitor for psoriasis), Cequa (cyclosporine for dry eye), and Odomzo (sonidegib for basal cell carcinoma). This business is the primary driver of Sun Pharma’s valuation premium over Indian pharma peers.

Q4. What is Ilumya and when could it face biosimilar competition?

Ilumya (tildrakizumab) is a biologic drug for plaque psoriasis. The compound patent protection expires in 2028, with biosimilar competition potentially entering the market in 2028-2029. The FDA approval of the biosimilar for review is an early-stage signal, not an immediate competitive threat.

Q5. What is Sun Pharma’s EBITDA margin?

Sun Pharma reported EBITDA margin of 27.8% in Q3 FY26, slightly declining from 28.2% a year ago. The margin remains among the highest in Indian large-cap pharma.

Q6. Who is the promoter of Sun Pharma?

Dilip Shanghvi (founder and Managing Director) and his family hold 54.5% of Sun Pharma — a high and confident promoter stake that has been stable for years.

Q7. Is Sun Pharma a good long-term investment?

Sun Pharma has the strongest specialty pharma pipeline among Indian companies, high promoter holding, and excellent EBITDA margins. At Rs 1,580, the valuation has corrected meaningfully from Rs 2,000. For investors with 3-year horizon, the risk-reward is more favourable than 12 months ago. Consult a SEBI-registered advisor.

Q8. What is Sun Pharma’s GLP-1 pipeline?

Sun Pharma has GL0034, an oral GLP-1 receptor agonist for obesity and diabetes, in Phase 2 clinical trials. This represents the longest-dated but potentially most significant pipeline asset if Phase 2 data is positive.